RNAZ Stock Analysis: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$8.61
0.96 (12.55%)
▲
5d:
+89.23%
30d:
+62.91%
90d:
+0.0%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: RNAZ is 36.5% above its trading range ($6.31). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: RNAZ is 36.5% above its trading range ($6.31). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $8.61, which is considered extended relative to its 30-day fair value range of $4.63 to $6.31.
Technical Outlook: Technically, RNAZ is in a strong downtrend. The price is approaching resistance at $6.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.5% recently.
Market Sentiment: RNAZ has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+16.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. The price is approaching resistance at $6.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.5% recently.
Market Sentiment: RNAZ has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.00 (+16.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.63 -
$6.31
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- BEARISH: Price significantly overextended (+36.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.5%)
- BULLISH: Trading below Wall St target ($10.00)
- WARNING: Recommendation downgraded due to 36.5% overvaluation
Trading Range Analysis
30-Day Trading Range
$4.63 -
$6.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$6.30
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.91
Wall Street Target
$10.00
(+16.1%)
Share & Embed Analysis
Last updated: July 02, 2026 10:32 PM ET
Data refreshes hourly during market hours. Next update: 11:32 PM
Data refreshes hourly during market hours. Next update: 11:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
